Trial Profile
A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs QN 165 (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Antisoma Research
- 16 Nov 2013 Status changed from active, no longer recruiting to completed according to results published in the Investigational New Drugs.
- 19 Mar 2010 Preliminary results indicate that AS 1411 has anti-cancer activity and is exceptionally well tolerated compared to most current antineoplastics. Trial data will be submitted to a forthcoming scientific meeting, according to an Antisoma media release.
- 13 Oct 2009 Initial results from this trial are expected before the end of 2009, according to an Antisoma media release.